Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorlatinib in ALK-Driven Relapsed or Refractory Neuroblastoma
NCT03107988Phase 1Completed
- Sponsor
- New Advances in Neuroblastoma Therapy
- Start
- Sep 2017
- Primary completion
- Aug 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 4
01
Overview
Phase 1, open-label trial of lorlatinib in neuroblastoma (13 cohorts), sponsored by New Advances in Neuroblastoma Therapy. Primary endpoints: Maximum Tolerated Dose / Recommended Phase 2 Dose at Day 28 and Non-Hematological and Hematological Toxicities. Started Sep 2017; status: completed.
02
Drugs
lorlatinib
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT03107988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03107988.